Oseltamivir

Generic Name
Oseltamivir
Brand Names
Ebilfumin, Tamiflu
Drug Type
Small Molecule
Chemical Formula
C16H28N2O4
CAS Number
196618-13-0
Unique Ingredient Identifier
20O93L6F9H
Background

Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...

Indication

According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...

Associated Conditions
Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B
Associated Therapies
-
Clinical Trials
Related News

Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

First Posted Date
2018-05-09
Last Posted Date
2020-10-22
Lead Sponsor
Unity Health Toronto
Target Recruit Count
30
Registration Number
NCT03520049
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.

Phase 2
Terminated
Conditions
Flu
Interventions
Drug: Oseltamivir
Drug: Placebos
Drug: Diltiazem
First Posted Date
2017-07-11
Last Posted Date
2023-02-06
Lead Sponsor
University Hospital, Lille
Target Recruit Count
85
Registration Number
NCT03212716
Locations
🇫🇷

Chu Amiens Picardie, Amiens, France

🇫🇷

CH ARRAS, Arras, France

🇫🇷

Ch Pierre Oudot Bourgoin Jallieu, Bourgoin-Jallieu, France

and more 16 locations

Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

First Posted Date
2017-01-23
Last Posted Date
2019-03-14
Lead Sponsor
MedImmune LLC
Registration Number
NCT03028909

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-63623872
Drug: Oseltamivir
First Posted Date
2017-01-18
Last Posted Date
2017-05-25
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
45
Registration Number
NCT03023852
Locations
🇧🇪

SGS Life Science Services, Antwerp, Belgium

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

First Posted Date
2016-11-03
Last Posted Date
2019-05-08
Lead Sponsor
Shionogi
Target Recruit Count
1436
Registration Number
NCT02954354

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

First Posted Date
2016-10-31
Last Posted Date
2019-11-19
Lead Sponsor
Shionogi
Target Recruit Count
2184
Registration Number
NCT02949011

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

First Posted Date
2016-09-05
Last Posted Date
2018-06-25
Lead Sponsor
Alios Biopharma Inc.
Target Recruit Count
68
Registration Number
NCT02888327
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)

Phase 4
Completed
Conditions
Drug Therapy, Combination
Interventions
Drug: Oseltamivir
Drug: Warfarin
First Posted Date
2016-05-23
Last Posted Date
2016-10-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
20
Registration Number
NCT02780622

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
Drug: Oseltamivir
First Posted Date
2016-03-24
Last Posted Date
2016-06-27
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
99
Registration Number
NCT02717754

A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

Phase 1
Completed
Conditions
End Stage Renal Disease
Interventions
Drug: Oseltamivir
First Posted Date
2015-12-01
Last Posted Date
2016-02-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT02617784
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy